Friday, 20 September 2019

J&J launches Robotics & Digital surgery QuickFire Challenge in Seoul

13 August 2018 | News

QuickFire Challenge seeks to identify and accelerate game-changing, early-stage innovations in the areas of robotics and digital surgery from around the world.

Johnson & Johnson Medical Korea Ltd. and Johnson & Johnson Innovation today announced the launch of the Seoul Innovation QuickFire Challenge: Robotics & Digital Surgery in collaboration with the Seoul Metropolitan Government and Korea Health Industry Development Institute (KHIDI).

 

The challenge invites innovators from around the world including start-ups, entrepreneurs, academics, scientists, and biotech researchers to submit ideas for robotics and digital health solutions with the potential to help surgeons and their patients.

 

The global competition also aims to help build a digital ecosystem in Korea and around the world where technologies enhance surgical performance, educate surgeons, and guide patients through to full recovery.

 

Up to two winners will receive up to KRW 150,000,000 (approximately US$134,000) in total grants, one year of residency at the Seoul Bio Hub, one year of mentorship and coaching from experts in science and commercialization at the Johnson & Johnson Family of Companies, and access to the JLABS global entrepreneurial community.

  

The QuickFire Challenges, launched by JLABS  the no-strings attached incubators of Johnson & Johnson Innovation  seek to empower and enable groundbreaking science and health solutions by encouraging students, entrepreneurs, researchers, and start-up companies, etc. to apply. The Robotics & Digital Surgery QuickFire Challenge will focus on the following innovation areas: 

Pre-op: Apps, Wearables, Planning Software

Intra-op: Robotics, Visualization, Neuromonitoring, Imaging

Post-op: Sensors, Wearables, Apps

 

The challenge aims to improve robotics and digital surgery by combining Johnson & Johnson Innovation's unique vision for collaboration in an open innovation model with the Seoul Metropolitan Government's efforts to drive innovation and commercialize its research outcomes; KHIDI's focus on identifying and solving critical problems within the ecosystem with healthcare research and innovative solutions; and Seoul Bio Hub's ability to foster and accelerate the development and commercialization of early-stage life-science solutions in the start-up community.

 

 

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account



Podcast

 

Survey Box

Is Pharma innovation getting inhibited in APAC?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls